These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 34885027)
1. Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate. D'Andrea MR; Cereda V; Coppola L; Giordano G; Remo A; De Santis E Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885027 [TBL] [Abstract][Full Text] [Related]
2. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. Bareche Y; Buisseret L; Gruosso T; Girard E; Venet D; Dupont F; Desmedt C; Larsimont D; Park M; Rothé F; Stagg J; Sotiriou C J Natl Cancer Inst; 2020 Jul; 112(7):708-719. PubMed ID: 31665482 [TBL] [Abstract][Full Text] [Related]
3. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033 [TBL] [Abstract][Full Text] [Related]
5. Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Yu T; Di G Chin J Cancer Res; 2017 Jun; 29(3):237-252. PubMed ID: 28729775 [TBL] [Abstract][Full Text] [Related]
6. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334 [TBL] [Abstract][Full Text] [Related]
7. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes. Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K J BUON; 2013; 18(3):608-13. PubMed ID: 24065471 [TBL] [Abstract][Full Text] [Related]
8. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8. Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N Gene; 2021 Aug; 792():145728. PubMed ID: 34022297 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features of indonesian breast cancers with different molecular subtypes. Widodo I; Dwianingsih EK; Triningsih E; Utoro T; Soeripto Asian Pac J Cancer Prev; 2014; 15(15):6109-13. PubMed ID: 25124582 [TBL] [Abstract][Full Text] [Related]
10. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer]. Wu SY; Tan Y; Guan YS Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945 [TBL] [Abstract][Full Text] [Related]
11. Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer. Dagher E; Simbault L; Abadie J; Loussouarn D; Campone M; Nguyen F Tumour Biol; 2020 Jan; 42(1):1010428319901052. PubMed ID: 31959092 [TBL] [Abstract][Full Text] [Related]
12. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer. Ring A; Kaur P; Lang JE BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919 [TBL] [Abstract][Full Text] [Related]
13. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026 [TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092 [TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer]. Liu ZF; Chen C; Yao XL; Sun SR Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638 [TBL] [Abstract][Full Text] [Related]
16. Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors. Naik A; Decock J Front Oncol; 2020; 10():598626. PubMed ID: 33324565 [TBL] [Abstract][Full Text] [Related]
17. Correlation study between the magnetic resonance imaging features of breast cancer and expression of immune molecular subtypes. Long N; Ran C; Sun J; Hao CJ; Sui YB; Li J; Shi YX; Zou ZX; Qu YH Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11518-11527. PubMed ID: 33275218 [TBL] [Abstract][Full Text] [Related]
18. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. García-Teijido P; Cabal ML; Fernández IP; Pérez YF Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325 [TBL] [Abstract][Full Text] [Related]
19. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. Stovgaard ES; Nielsen D; Hogdall E; Balslev E Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430 [TBL] [Abstract][Full Text] [Related]
20. Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer. Takada K; Kashiwagi S; Asano Y; Goto W; Kouhashi R; Yabumoto A; Ishihara S; Morisaki T; Shibutani M; Tanaka H; Hirakawa K; Ohira M BMC Womens Health; 2021 May; 21(1):225. PubMed ID: 34051785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]